Regulators

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

FDA Puts Alzheimer’s Prevention on the Trial Agenda

Energy drinks went mainstream before their cardiac safety evidence did

HRR Testing Moves Upfront in Prostate Cancer

ALS Immune Signals Depend on Where You Look

FDA Redraws the TMB-High Treatment Line

Ebola’s Vaccine Trial Enters New Territory

ESCAT v2 Makes Resistance Clinically Actionable

Enhertu Stumbles in Early Breast Cancer

Endometrial Cancer Gets a Strong ADC Win
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
